MedTrace Logo

Lidocaine Infusion as a Treatment for Cocaine Relapse and Craving

NCT01929343 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 84

Last updated 2020-12-31

Study results available
· View outcomes & findings →

Summary

We propose that the systemic administration of lidocaine following the induction of cue-induced craving, relative to saline plus cue-induced craving or lidocaine without cue-induced craving, will block the reconsolidation of cue memories. This will lead to a reduction in cue-induced craving upon repeated testing as well as subsequent cocaine use and basal craving.

Conditions

  • Cocaine Addiction

Interventions

DRUG

lidocaine following cue-induced craving

as described in Arm Description

DRUG

lidocaine following neutral stimulus

as described in Arm Description

DRUG

saline

as described in Arm Description

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Bryon Adinoff

    lead OTHER

Principal Investigators

  • Bryon Adinoff, MD · UT Southwestern Medical Center, VA North Texas Health Care System

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
25 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-01-31
Primary Completion
2016-03-31
Completion
2016-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01929343 on ClinicalTrials.gov